Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has met its enrollment target of 330 patients in US centers for its Phase IIb trial for its major depressive disorder drug. As a result of this rapid enrollment, Epix expects to announce results of this trial in the first quarter of 2008.
Subscribe to our email newsletter
Furthermore, Epix has completed enrollment of its Phase IIa clinical trial of PRX-03140 in Alzheimer’s disease and reaffirmed that it is on track to announce the findings of this study by the end of 2007.
PRX-00023 (highly selective 5-HT1A partial agonist)and PRX-03140 (selective for the 5-HT4 receptor in the brain) were discovered by using the company’s proprietary G-Protein Coupled Receptors (GPCR) modeling, screening and lead optimization technology, Epix said.
Michael Kauffman, CEO of Epix, said: “We are very pleased to achieve these significant milestones for these two important clinical trials. We believe that the rapid pace at which we were able to recruit patients into the phase IIb major depressive disorder trial is indicative of the interest in, and need for, new and improved treatments for depression.”